Bayer HealthCare is selling its equine assets to Merial, Inc. Bayer says the deal will see its Legend®/Hyonate® (hyaluronate sodium) and Marquis® (ponazuril) go to Merial by the first quarter 2015.
“This transaction will allow our business to focus on innovation and growth in core segments for both companion and farm animals,” said Dr. Dirk Ehle, Head of Bayer HealthCare’s Animal Health Division. “These equine products have no strategic relevance for our business and represent less than 2 percent of our worldwide sales.”
Hyaluronate sodium, marketed worldwide for over two decades as Legend® or Hyonate®, is an injectable solution that treats noninfectious joint dysfunction in horses.
Marquis® (ponazuril) Antiprotozoal Oral Paste, marketed in North America for over a decade, treats equine protozoal myeloencephalitis (EPM) – a disease that affects the central nervous system in horses.